盖莱克-1 是心力衰竭的标记物,但不是中介物,具有保存的喷射分数
Jean W Wassenaar1,2, C Duncan Smart3, Daniel J Fehrenbach4
1Department of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.
Hypertension (Dallas, Tex. : 1979)
|January 30, 2026
概括
较高的加勒-1水平表明心力衰竭风险增加,患者的预后更差. 然而,在临床前的模型中,加勒-1缺乏并没有改变心力衰竭的进展,这表明它是一种标记物,而不是原因.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 生物标志物 生物标志物
背景情况:
- 免疫系统在心力衰竭中的心脏重塑中发挥着至关重要的作用,心脏衰竭具有保存的喷射分数 (HFpEF).
- 在临床前的HFpEF模型中,发现碳水化合物结合蛋白 Galectin-1 (Lgals1) 在心脏髓状细胞中被上调.
- 这项研究使用临床前模型和人类队列研究了加列-1在HFpEF中的作用.
研究的目的:
- 确定加勒-1在心力衰竭的发病过程中的作用,以保存的喷射分数 (HFpEF).
- 评估循环中的加勒-1水平与人类人群中HFpEF风险和预后的相关性.
- 通过小鼠的遗传缺失模型,研究加勒-1和HFpEF之间的因果关系.
主要方法:
- 在人类队列中,使用奥林克近距离延伸试验量化了加勒-1水平.
- 在小鼠中使用脱氧皮质乙酸盐-盐模型诱导心力衰竭与保存的喷射分数 (HFpEF).
- 用于评估其功能作用的,使用了具有骨髓特异性和整体缺失加勒-1的小鼠.
主要成果:
- 在临床前的HFpEF模型和人类心力衰竭患者 (英国生物库) 中,血甲烯-1升高.
- 在急性HFpEF患者中,较高的加勒-1水平与发生性心力衰竭的风险增加以及NT-proBNP升高相关.
- 缺乏加勒-1的小鼠 (全球或骨髓细胞) 在HFpEF的发展上没有差异.
结论:
- 循环中高水平的加勒-1与心力衰竭风险增加和预后较差有关,由较高的NT-proBNP水平表明.
- 在临床前的HFpEF模型中,加勒丁-1的缺失没有影响心血管表型.
- 这些发现表明,加勒-1 作为HFpEF的生物标志物,而不是直接的因果调解者.
相关概念视频
01:29Heart Failure II: Pathophysiology
907
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
907
01:17Pathophysiology of Heart Failure
3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
01:27Heart Failure I: Introduction
877
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
877
01:22Heart Failure VI: Adjunct Therapies
332
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
332
01:22Heart Failure Drugs: Diuretics
963
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963
01:30Heart Failure V: Medical Management
308
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
308